Cargando…
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo
Mobilized peripheral blood cells (MPBCs) graft and peripheral blood cells apheresis are used for bone marrow transplantation and for treatment of graft versus host disease (GvHD). We demonstrate that a short treatment of MPBCs with Fas ligand (FasL, CD95L) for 2 h using a closed automated cell proce...
Autores principales: | Rodionov, Galina, Rosenzwaig, Michal, Tzadok, Michal Schrift, Kvint, Moran, Gevir, Elazar, Zorde-Khvalevsky, Elina, Peled, Amnon, Yarkoni, Shai, Ofer, Amos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088133/ https://www.ncbi.nlm.nih.gov/pubmed/35538142 http://dx.doi.org/10.1038/s41409-022-01698-3 |
Ejemplares similares
-
Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance
por: Levy-Barazany, Hilit, et al.
Publicado: (2020) -
Fas-L promotes the stem cell potency of adipose-derived mesenchymal cells
por: Solodeev, Inna, et al.
Publicado: (2018) -
Multistep, effective drug distribution within solid tumors
por: Shemi, Amotz, et al.
Publicado: (2015) -
The Chondrogenic Potential of Mesenchymal Cells and Chondrocytes from Osteoarthritic Subjects: A Comparative Analysis
por: Agar, Gabriel, et al.
Publicado: (2011) -
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity
por: Cendrowicz, Ewa, et al.
Publicado: (2022)